ライフサイエンスコーパス: antiresorptive

1 tive than alendronate, which acts only as an antiresorptive.

2 in rats can be ameliorated by bone-targeted antiresorptives.

3 ng a window for prophylaxis with long-acting antiresorptives.

4 at intervals of 2 weeks, displays a powerful antiresorptive action in vivo.

5 Although the antiresorptive action of estrogen arises from the inhibi

6 However, the antiresorptive action of estrogen decreased the extent o

7 This profound and lasting antiresorptive action of TSH is mimicked in cells that g

8 Representative inhibitors have demonstrated antiresorptive activity both in vitro and in vivo and th

9 e adsorption assay, and demonstrates in vivo antiresorptive activity in a parathyroid hormone-induced

10 This antiresorptive activity was abolished by phenylmethylsul

11 dronate (IG9402, a bisphosphonate that lacks antiresorptive activity) at 10(-9) to 10(-6) M prevented

12 r (AP22408) of Src that demonstrates in vivo antiresorptive activity.

13 impact of a locally or systemically applied antiresorptive agent (alendronate) on simvastatin-induce

14 thyroid hormone in the future, the choice of antiresorptive agent should be carefully considered.

15 Alendronate (ALN) is an antiresorptive agent widely used for the treatment of os

16 e that combining parathyroid hormone with an antiresorptive agent will enhance its effect on bone min

17 is also possible that the combination of an antiresorptive agent with an anabolic agent could be mor

18 reatment (parathyroid hormone followed by an antiresorptive agent), which aims to maintain or build o

19 in the presence of zoledronic acid, a potent antiresorptive agent.

20 if parathyroid hormone is not followed by an antiresorptive agent.

21 y, whose appearance could be prevented by an antiresorptive agent.

22 ologists were less likely to be treated with antiresorptive agents (OR 0.49 [95% CI 0.28-0.86]).

23 use parathyroid hormone in combination with antiresorptive agents and sequentially are reviewed.

24 Novel antiresorptive agents are being developed.

25 The antiresorptive agents are clearly able to preserve bone

26 Antiresorptive agents are widely used to treat osteoporo

27 Therapy with individual antiresorptive agents has been shown to be effective for

28 To reduce bone loss and improve strength, antiresorptive agents have been instituted.

29 e effects of these pharmacologically diverse antiresorptive agents on gene expression in bone has not

30 Antiresorptive agents such as bisphosphonates are used w

31 ciated bone disease are available, including antiresorptive agents such as denosumab and bisphosphona

32 rapy approaches with parathyroid hormone and antiresorptive agents to optimize efficacy outcomes.

33 fonamides like 55 form a new class of potent antiresorptive agents with possible therapeutic use in d

34 Antiresorptive agents, especially bisphosphonates, appea

35 se findings suggest that, among women taking antiresorptive agents, greater increases in BMD are asso

36 pounds for the development of a new class of antiresorptive agents.

37 rug therapy for osteoporosis including novel antiresorptive and anabolic agents that may become avail

38 Bis-enoxacin, which has both antiresorptive and antibiotic activities, was more effec

39 mulation of this metabolite accounts for the antiresorptive and antimacrophage effects of clodronate.

40 moving beyond traditional monotherapies with antiresorptives and anabolic agents into new combination

41 Surprisingly, the bone-targeted antiresorptives bis-enoxacin and alendronate inhibited i

42 The exact mechanisms of action of antiresorptive bisphosphonate drugs remain unclear, alth

43 a new pyridinyl bisphosphonate, is a potent antiresorptive bone agent.

44 Botanicals and their relation to bone antiresorptive capacity, cognitive function, vascular ef

45 helper cells that can function as a pro- or antiresorptive cytokine, but the reason why IFN-gamma ha

46 s with additional drugs, especially the bone antiresorptive denosumab.

47 , calcium and vitamin D supplementation, and antiresorptive drug treatment.

48 gnificant association between overall use of antiresorptive drugs and the presence of knee pain and r

49 Bisphosphonate antiresorptive drugs are the approved treatment for soli

50 ures are needed to determine whether and how antiresorptive drugs can be optimally used in conjunctio

51 While antiresorptive drugs have been the cornerstone of osteop

52 arily by stimulating bone formation, whereas antiresorptive drugs reduce bone resorption.

53 Antiresorptive drugs were prescribed in 26%, 12%, 7%, an

54 patients receiving long-term treatment with antiresorptive drugs.

55 mong these women, 214 (26.2%) were receiving antiresorptive drugs.

56 Overall these studies suggest that the antiresorptive effects of anti-TNF therapy are related t

57 group (p = 0.002), consistent with the known antiresorptive effects of bisphosphonates.

58 irect evidence that the antiinflammatory and antiresorptive effects of clodronate on macrophages and

59 These data demonstrate the potent antiresorptive effects of muRANK.Fc in vivo as well as h

60 The antiresorptive effects of TNF inhibitors are likely rela

61 e critical cytokine mediating the downstream antiresorptive effects of TSH on the skeleton.

62 R = 0.74, p < 0.0001) are closely linked to antiresorptive efficacy.

63 Several novel antiresorptive mechanisms are currently under considerat

64 with 1995-1998, and the use of prescription antiresorptive medication increased approximately 2-fold

65 or measurement of bone mass, prescription of antiresorptive medication, and use of over-the-counter c

66 s (ONJ) is a rare but severe complication of antiresorptive medications, such as bisphosphonates, use

67 ss a conceptual framework of agents that are antiresorptive or anabolic, and review pathways that aff

68 ess fracture risk, and reduce that risk with antiresorptive or other available therapies.

69 The CoMFA predicted (rat) bone antiresorptive pLED values are in agreement with literat

70 the effectiveness of a regimen combining the antiresorptive properties of nasal calcitonin with the o

71 In keeping with its antiresorptive properties, ritonavir impairs receptor ac

72 TIL may influence its anti-inflammatory and antiresorptive properties.

73 Transplant recipients were treated with an antiresorptive regimen that included a bisphosphonate st

74 ated, and no causal association between bone antiresorptive regimens and MRONJ has yet been establish

75 distinguishing features of the anabolic and antiresorptive therapies for the treatment of osteoporos

76 bitors of transforming growth factor-beta or antiresorptive therapies may be effective enhancers of a

77 Current antiresorptive therapies provide limited benefit, and no

78 seful to assess the response to anabolic and antiresorptive therapies, to assess compliance to therap

79 orosis has traditionally involved the use of antiresorptive therapies.

80 y result in the development of improved bone antiresorptive therapies.

81 to quantify bone turnover in women receiving antiresorptive therapy compared with that of untreated c

82 would provide a strong rationale for use of antiresorptive therapy for the prevention and treatment

83 continuation of this trial, we asked whether antiresorptive therapy is required to maintain gains in

84 While antiresorptive therapy is the mainstay of OI treatment,

85 This suggests that antiresorptive therapy may be discontinued at the end of

86 o two years or less, the question of whether antiresorptive therapy should follow parathyroid hormone

87 Antiresorptive therapy with a bisphosphonate decreases t

88 pausal osteoporosis, but whether combination antiresorptive therapy with hormones and bisphosphonates

89 astogenesis and is a potential candidate for antiresorptive therapy.

90 agents might have greater potential than the antiresorptives to increase bone mass and to decrease fr

91 protection compared with either anabolic or antiresorptive treatment alone.

92 tomy and additionally changed by one or more antiresorptive treatment.

93 TCG) finds convincing evidence that adjuvant antiresorptive treatments provide persistent benefits to

94 Antiresorptive treatments such as bisphosphonates preven

95 nd systemic inflammation, and the success of antiresorptive treatments will rely on how effectively t